Để khẳng định sự cú mặt của cDNA-NK1 trong cỏc vector biểu hiện, hai vector biờ̉u hiờ ̣n pCDNA3-NK1-11 và peGFP -N1-NK1-5 được giải trình tự m ột chiờ̀u từ đầu 5’ của đoạn chốn NK1 bằng mụ̀i của vector.
Kờ́t quả giải trình tự cDNA-NK1 trong hai hờ ̣ thụ́ng vector biờ̉u hiờ ̣n trờn đờ̀u cho thấy hơn 750 bp phớa đầu 5’ của cDNA-NK1 khụng có bṍt kỳ sự sai khác nào so với trình tự cDNA gụ́c trong vector tỏch dũng pNK1-3. Điờ̀u đó chứng tỏ rằng chỳng tụi đó thành cụng trong việc thiết kế vector bi ểu hiện mang cDNA hoàn chỉnh mó húa cho thụ thể neurokinin-1 ở người Việt Nam.
KẾT LUẬN VÀ KIẾN NGHỊ KẾT LUẬN
Với những kết quả thu được chỳng tụi đưa ra những kết luận sau:
1. Tỏch dũng thành cụng cDNA hoàn chỉnh mó húa cho thụ thể neurokinin – 1 ở phổi người Việt Nam. cDNA-NK1 cú kớch thước 1338 bp trong đú cú 5 nucleotide (ở cỏc vị trớ 184, 333, 370, 641, 996) khụng giống với trỡnh tự cDNA- NK1 trong ngõn hang dữ liệu, chứng tỏ sự đa hỡnh của gen mó cho thụ thể NK1 ở người Việt Nam.
2. Thiết kế thành cụng vector biểu hiện pCDNA3 và pEGFP-N1 mang cDNA mó cho thụ thể NK1 phõn lập từ phổi của người Việt Nam.
KIẾN NGHỊ
Chuyển nhiễm vector biểu hiện pCDNA3 và pEGFP-N1 mang cDNA-NK1 vào hệ thống tế bào động vật để biểu hiện thụ thể neurokinin – 1.
TÀI LIỆU THAM KHẢO
Tiếng Việt
1. Vừ Thị Thương Lan (2004), Sinh học phõn tử, Nhà xuất bản Đại học Quốc gia, Hà Nội.
2. Đinh Đoàn Long, Đỗ Lờ Thăng (2008), Cơ sở di truyền học phõn tử và tế bào, NXB Đại học Quốc gia, Hà Nội.
Tiếng Anh
3. Almeida T. A., Rojo J., Nieto P. M., Pinto F. M., Hernandez M., Martớn J. D., Candenas M. L. (2004), “Tachykinins and tachykinin receptors: structure and activity relationships”, Bentham Science Publishers, 11, pp. 2045-2081. 4. Alberts B., Johnson A., Lewis J., et al. (2002), Molecular Biology of the
Cell. 4th edition, New York: Garland Science.
5. Baker S. J., Morris J. L., Gibbins I. L. (2003), “Cloning of a C-terminally truncated NK-1 receptor from guinea-pig nervous system”, Brain Res Mol Brain Res., 11(1-2), pp. 136-47.
6. Berger M. (2012), “The Role of Neurokinin-1 Receptor in the Microenvironment of Inflammation and Cancer”, The Scientific World Journal, 2012, pp. 381434.
7. Bonner T. I., Affolter H. U., Young A. C., Young W. S. (1987), “A cDNA encoding the precursor of the rat neuropeptide, neurokinin B”, Brain Res,388, pp. 243–249.
8. Boot J. D., de Haas S., Tarasevych S., et al. (2007), "Effect of an NK1/NK2 receptor antagonist on airway responses and inflammation to allergen in asthma", Am. J. Respir. Crit. Care Med., 175(5), pp. 450–457.
9. Buck S. H., Burcher E., Shults C. W., Lovenberg W., O'Donohue T. L. (1984), “Novel pharmacology of substance K-binding sites: a third type of tachykinin receptor”, Science, 226(4677), pp. 987–989.
10. Buck S. H., Helke C. J., Burcher E., Shults C. W., O'Donohue T. L. (1986), “Pharmacologic characterization and autoradiographic distribution of
binding sites for iodinated tachykinins in the rat central nervous system”,
Peptides, 7(6), pp. 1109-1120.
11. Caberlotto L., Hurd Y. L., Murdock P., Wahlin J. P., Melotto S., Corsi M., Carletti R.(2003), “Neurokinin 1 receptor and relative abundance of the short and long isoforms in the human brain”, Eur J Neurosci, 17(9), pp. 1736- 1746.
12. Carter M. S., Krause J. E. (1990), "Structure, expression, and some regulatory mechanisms of the rat preprotachykinin gene encoding substance P, neurokinin A, neuropeptide K, and neuropeptide gamma", J. Neurosci., 10(7), pp. 2203–2214.
13. Chamindi S., Nassima A. D., Jennie Z. M., Guobo C., Bankole A. J., Ming D. L. (2009), “Susceptibility locus in neurokinin-1 receptor gene associated with alcohol dependence”, Neuropsychopharmacology, 34(11), pp. 2442– 2449.
14. Chang M. M., Leeman S. E. (1970), “Isolation of a sialagogic peptide from bovine hypothalamic tissue and its characterization as substance P.”, J. Biol Chem, 245, pp. 4784–4790.
15. Cinzia S., Giovanna I., Giuliana F. E., Severo S.,Vittorio E. (2002), “The Tachykinin Peptide Family”, Pharmacological Reviews, 54(2), pp. 285- 322. 16. Cao Y. Q., Mantyh P. W., Carlson E. J., Gillespie A. M., Epstein C.
J., Basbaum A. I. (1998), “Primary afferent tachykinins are required to experience moderate to intense pain”, Nature, 392(6674), pp. 390-394.
17. CreutzfeldtW. (1996), “Carcinoid tumors: development of our knowledge”, World J Surg, 20, pp. 13126–13143.
18. De Felipe C., Herrero J. F., O'Brien J. A., Palmer J. A., Doyle C. A., Smith A. J., Laird J. M., Belmonte C., Cervero F., Hunt S. P. (1998), “Altered nociception, analgesia and aggression in mice lacking the receptor for substance P”, Nature., 392(6674), pp. 394-397.
19. Erspamer V. (1949), “Ricerche preliminari sulla moschatina”, Experientia, 5, pp. 79.
20. Erspamer V. (1994), “Bioactive secretions of the integument in Amphibian Biology. I. The Integuments, eds Heatwole H., Barthalmus G. T., Surrey Beatty & Sons, Chipping Norton, NSW, Australia, pp. 178–350.
21. Euler U. S., Gaddum J. H. (1931), “An unidentified depressor substance in certain tissue extracts”, J Physiol., 72(1), pp. 74–87.
22. Fong T. M., Anderson S. A., Yu H., Huang R. R., Strader C. D. (1992), “Differential activation of intracellular effector by two isoforms of human neurokinin-1 receptor”, Mol Pharmacol, 41(1), pp. 24-30.
23. Gerard N. P., Eddy R. L. J., Shows T. B., Gerard C. (1990), “The human neurokinin A (substance K) receptor. Molecular cloning of the gene, chromosome localization, and isolation of cDNA from tracheal and gastric t issues”, J Biol Chem, 265(33), pp. 20455-20462.
24. Gerard N. P., Garraway L. A., Eddy R. L., Shows T. B,. (1991), “Human substance P receptor (NK-1): organization of the gene, chromosome localization and functional expression of cDNA clones”, Biochemistry,
30(44), pp. 10640-10646.
25. Groneberg D. A., Harrison S., Dinh Q. T., Geppetti P., Fischer A. (2006), "Tachykinins in the respiratory tract", Curr Drug Targets, 7(8), pp. 1005– 1010.
26. Guard S., WatsonS. P. (1991), “Tachykinin receptor types: classification and membrane signaling mechanism”, Neurochem Int, 18, pp. 149–165.
27. Ho W. Z., Lai J. P., Zhu X. H., Uvaydova M., Douglas S. D. (1997), “Human monocytes and macrophages express substance P and neurokinin- 1 receptor”, Journal of Immunology, 159, pp. 5654–5660.
28. Hopkins B. P., Steven J. D., Petra B., Ian G., Alexander (1991), “Isolation and characterisation of the human lung NK-1 receptor cDNA”, Biochemical and Biophysical Research Communications, 180(2), pp. 1110-1117.
29. Hurowitz E. H., Melnyk J. M., Chen Y. J., Kouros-Mehr H., Simon M.I., Shizuya H. (2000), "Genomic characterization of the human heterotrimeric G protein alpha, beta, and gamma subunit genes", DNA Res, 7(2), pp. 111–120.
30. Jian P. L., Saien L., Florin T., Morris F. T., Laurie E. K., Susan E. L., Steven D. D. (2008), “Differences in the length of the carboxyl terminus mediate function properties of neurokinin-1 receptor”, Proceedings of the National
Academy of Sciences of the United States of America, 105 (34), pp.
12605-12610).
31. Kangawa K., Minamino N., Fukuda A., Matsuo H. (1983), “Neuromedin K: a novel mammalian tachykinin identified in porcine spinal cord”,
Biochem Biophys Res Commun., 114(2), pp. 533-540.
32. Kathryn E. M., Catherine D. S., Tung M. F. (1994), “Expression and solubilization of a recombinant human neurokinin-1 receptor in insect cells”,
Journal of receptor research, 14(1), pp. 63-73.
33. Kimura S., Goto K., Ogawa T., Sugita Y., Kanazawa (1984), “Pharmacological characterization of novel mamamlian tachykinin, neurokinin alpha and neurokimin beta”, Neuroscience Research, 2, pp. 97- 104.
34. Marcinkiewicz N., Seidah N. G., Chretien M. (1993), “Les convertases des prohormones et le systộme nerveus”, Mộdecine/Science (Wash DC), 9, pp. 553–561.
35. Nakajima Y., Tsuchida K., NegishiM., Ito S., Nakanishi S. (1992), “Direct linkage of three tachykinin receptors to stimulation of both phosphatidylinositol hydrolysis and cyclic AMP cascades in transfected Chinese hamster ovary cells”, J Biol Chem, 267, pp. 2437–2442.
36. Nakanishi S. (1987), “Substance P precursor and kininogen: their structures, gene organizations and regulation”, Physiol Rev, 67, pp. 1117–1142.
37. Nawa H., Kotani H., Nakanishi S. (1984), “Tissue-specific generation of two preprotachykinin mRNAs from one gene by alternative RNA splicing”,
Nature (Lond), 312, pp. 729–734.
38. Oka Y., Saraiva L. R., Kwan Y. Y., Korsching S. I. (2009), “The fifth class of G alpha proteins”, Proc Natl Acad Sci USA, 106(5), pp. 1484-1489.
39. Page N. M. (2004), “Hemokinins and endokinins”, Cell Mol Life Sci, 61, pp. 1652-1663.
40. Pernow B (1983), “Substance P”, Pharmacol Rev, 35(2), pp. 85-141.
41. Rosso M., Mu˜noz M. (2006), "Pharmacology Guide: In vitro pharmacology: concentration-response curves.", GlaxoWellcome.
42. Quartara L.; Maggi C. A. (1997), "The tachykinin NK1 receptor. Part I: Ligands and mechanisms of cellular activation", Neuropeptides, 31(6), pp. 537–563.
43. Rogers M. P., Blackburn L. (2010), “Use of neurokinin-1 receptor antagonists in patients receiving moderately or highly emetogenic chemotherapy”, Clin J Oncol Nurs., 14(4), pp. 500-504.
44. Rupnipak M. J. N, Kramer M. S, (2002), “Substance P and related tachykinins”, Neuropsychopharmacology: The Fifth Generation of Progress, pp. 169 – 177.
45. Severini C., Salvadori S., Guerrini R., Falconieri-Erspamer G., Mignogna G., ErspamerV. (2000), “Parallel bioassay of 39 tachykinins on 11 smooth muscle preparations. Structure and receptor selectivity/affinity relationship”,
Peptides, 21, pp. 1587–1595.
46. Spiegel A. M. (1987), “Signal transduction by guanine nucleotide binding proteins”, Mol Cell Endocrinol, 49(1), pp. 1-16.
47. Steiner D. F., Smeekens S. P., Ohagi S., Chan S. J. (1992), “The new enzymology of precursor processing endoproteases”, J Biol Chem,267, pp. 23435–23438.
48. Steven D. D. Kenvin G. L, Jian P. L (2008), “Neurokinin-1 receptor mARN expression diffirences in brains of HIV-infected individuals”, Journal of the neurological sciences, 272(1-2), pp. 174-177.
49. Stratowa C., Machat H., Burger E., Himmler A., Schafer R., Spevak W., Weyer U., Wiche-Castanon M., Czernilofsky A. P. (1995), “Functional characterization of the human neurokinin receptor NK1, NK2, NK3 based on
a cellular assay system”, J. of receptor and signal transduction research, 15(1-4), pp. 617-630.
50. Studer R., Trzeciak A., Lergier W. (1973), “Isolierung und Aminosauren Sequenz von Substanz P aus Pferdedarm”, Helv Chim Acta, 56, pp. 860– 866.
51. Tae H. J., Mathis G., Inhae J. (1998) “G protein – coupled receptors”, The Journal of Biological Chemistry, 273(28), pp. 17299-17302.
52. Vassilatis D. K., Hohmann J. G., Zeng H., Li F., Ranchalis J. E., Mortrud M. T., Brown A., Rodriguez S. S., Weller J. R., Wright A. C., Bergmann J. E., Gaitanaris G. A., (2003), “The G protein-coupled receptor repertoires of human and mouse”, PNAS, 100, pp. 4903–4908.
53. Wettschureck N., Offermanns S. (2005), "Mammalian G proteins and their cell type specific functions", Physiol. Rev., 85(4), pp. 1159–204.
54. Yu Z., Liwei L., Caren F., Gillian E. W., Christopher J. P. (2000), “Hemokinin is a hematopoietic-specific tachykinin that regulates B lymphopoiesis”, Nature Immunology, 1, pp. 392 – 397.
55. Zimmer A., Zimmer A. M., Baffi J., Usdin T., Reynolds K., Kửnig M., Palkovits M., Mezey E. (1998), “Hypoalgesia in mice with a targeted deletion of the tachykinin 1 gene”, Proc Natl Acad Sci USA., 95(5), pp. 2630-2635. Trang web 56. http://gpcr.scripps.edu/ 57. http://www.nobelprize.org/nobel_prizes/medicine/laureates/1994/press.html 58. http://www.uniprot.org/uniprot/P25 59. http://www.ncbi.nlm.nih.gov/nuccore/M81797.1 60. http://themedicalbiochemistrypage.org/signal-transduction.php 61. http://pharmrev.aspetjournals.org/content/54/2/285/T5.expansion.ht